Mayer Gottfried, Vogel Vitali, Weyermann Jörg, Lochmann Dirk, van den Broek Jacomina A, Tziatzios Christos, Haase Winfried, Wouters Daan, Schubert Ulrich S, Zimmer Andreas, Kreuter Jörg, Schubert Dieter
Institut für Biophysik, Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, Haus 74, 60590 Frankfurt am Main, Germany.
J Control Release. 2005 Aug 18;106(1-2):181-7. doi: 10.1016/j.jconrel.2005.04.019.
Nanoparticles prepared by self-assembly from oligonucleotides (ONs), protamine free base, and human serum albumin ("ternary proticles") are spheres of diameters around 200 nm. Substitution of the protamine free base by protamine sulfate leads to proticles of only around 40 nm in diameter with otherwise unchanged properties. The availability of drug delivery systems of very similar composition but grossly different size may be advantageous when dealing with cells which show size-dependent particle uptake. These nanoparticles are promising candidates for ON delivery to cells because of the following reasons: (1) They are stable for several hours in solutions of up to physiological ionic strength; (2) they are efficiently taken up by cells; (3) after cellular uptake, they easily release the ONs even when these are present as phosphorothioates.
通过寡核苷酸（ONs）、游离精蛋白碱和人血清白蛋白自组装制备的纳米颗粒（“三元颗粒”）是直径约200 nm的球体。用硫酸鱼精蛋白替代游离精蛋白碱会导致直径仅约40 nm的颗粒，而其他性质不变。在处理表现出大小依赖性颗粒摄取的细胞时，具有非常相似组成但大小差异很大的药物递送系统可能具有优势。由于以下原因，这些纳米颗粒有望成为将ON递送至细胞的候选物：（1）它们在高达生理离子强度的溶液中稳定数小时；（2）它们能被细胞有效摄取；（3）细胞摄取后，即使ON以硫代磷酸酯形式存在，它们也能轻易释放ON。
